Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Not all neuroendocrine tumors respond equally to radionuclide therapy. A real-world study of 209 patients found that pancreatic and unknown-primary NETs had the highest response rates to 177Lu-DOTATATE, while bone and peritoneal metastases lagged behind. Still, stable disease was achieved in the majority of lower-responders, suggesting the treatment offers broad benefit.
A real-world, retrospective study presented at the 2026 NANETS Multidisciplinary NET Medical Symposium reveals that responses to 177Lu-DOTATATE — a targeted radionuclide therapy for neuroendocrine tumors (NETs) — vary meaningfully depending on where the tumor originates and where it spreads. Researchers analyzed electronic health records from 209 patients with metastatic NETs treated at Ochsner Medical Center over a decade (2015–2025).
Pancreatic and unknown-primary NETs led the pack with overall response rates (ORR) of 52.5% and 52%, respectively. Gastrointestinal and lung primaries trailed at roughly 24% ORR. Patients with bone and peritoneal metastases had the lowest response rates, though stable disease was achieved in 65–74% of those patients — a meaningful outcome in a disease where progression control matters.
By the Numbers:
Why it matters: These findings can help oncologists set more realistic expectations and tailor treatment conversations based on tumor location — a step toward more personalized care for NET patients.
